Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-04-21
DOI
10.1038/s41591-020-0833-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials
- (2019) Michael J Grayling et al. JNCI-Journal of the National Cancer Institute
- Comparison of treatment effect from randomised controlled phase II trials and subsequent phase III trials using identical regimens in the same treatment setting
- (2019) Fei Liang et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 Study of ABT-122, a TNF- and IL-17A-Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis With Inadequate Methotrexate Response
- (2018) Philip J. Mease et al. Arthritis & Rheumatology
- Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).
- (2017) Monica Tang et al. JOURNAL OF CLINICAL ONCOLOGY
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
- (2016) Philip J. Mease et al. Arthritis & Rheumatology
- Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study
- (2015) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial
- (2015) Tsutomu Takeuchi et al. Modern Rheumatology
- The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ra
- (2015) Michael E. Weinblatt et al. Arthritis & Rheumatology
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study
- (2014) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
- (2014) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
- (2014) T. L. Vollmer et al. JOURNAL OF NEUROLOGY
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- Antagonist
- (2014) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study
- (2014) Tsutomu Takeuchi et al. Modern Rheumatology
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
- (2014) Mark C. Genovese et al. Arthritis & Rheumatology
- Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- (2014) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Logistic Regression With Multiple Random Effects: A Simulation Study of Estimation Methods and Statistical Packages
- (2013) Yoonsang Kim et al. AMERICAN STATISTICIAN
- A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate
- (2013) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
- (2013) Iain B McInnes et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- Influence of trial sample size on treatment effect estimates: meta-epidemiological study
- (2013) A. Dechartres et al. BMJ-British Medical Journal
- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial 21011 (NCT00
- (2012) S. Whittaker et al. BRITISH JOURNAL OF DERMATOLOGY
- Assumptions of Expected Benefits in Randomized Phase III Trials Evaluating Systemic Treatments for Cancer
- (2012) H. K. Gan et al. JNCI-Journal of the National Cancer Institute
- Discounting phase 2 results when planning phase 3 clinical trials
- (2012) S. Kirby et al. PHARMACEUTICAL STATISTICS
- American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
- (2011) D. T. Felson et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
- (2011) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Key Concepts of Clinical Trials: A Narrative Review
- (2011) Craig A. Umscheid et al. POSTGRADUATE MEDICINE
- Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
- (2010) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
- (2010) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
- (2008) D Aletaha et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More